Old Guard vs New Wave Comparing Warfarin and New Oral Anticoagulants
1Dr. Qurrat-ul-ain Bukhari, 2Dr.Shireen Nazir, 3Mansoor Musa, 4Qamar Abbas, 5Isma Abbas, 6Faiza Maqsood
1Altamash Institute of Dental Medicine.
2Assistant professor Altamash institute of dental medicine.
3Agha Khan Hospital Karachi.
4PIMS Islamabad
5UHS Lahore
6Liaquat Hospital Karachi.
Background: Warfarin has historically been the cornerstone of oral anticoagulation, particularly in patients with atrial fibrillation (AF) and venous thromboembolism (VTE). However, its narrow therapeutic index, dietary and drug interactions, and need for frequent INR monitoring have led to challenges in long-term management. Novel oral anticoagulants (NOACs)—including apixaban, rivaroxaban, dabigatran, and edoxaban—have emerged as safer and more convenient alternatives due to fixed dosing and reduced bleeding risk profiles [1–4].
Aim: To compare the efficacy, safety, monitoring requirements, and patient adherence between Warfarin and NOACs using published evidence, trend-aligned local hospital data, and a structured patient survey.
Methods: Peer-reviewed studies published from 2018 to 2024 were reviewed. Mean data reflecting anticoagulant prescribing trends among 80 patients from local tertiary private hospitals were used to establish real-world usage patterns. A structured 30-patient survey assessed adherence, satisfaction, and perceived treatment burden. Descriptive statistics and hazard ratios were used to interpret findings.
Results: Clinical trials and meta-analyses indicate that NOACs reduce major bleeding risk by 15–20% compared to Warfarin while maintaining non-inferior or superior efficacy in stroke prevention (HR 0.89; 95% CI 0.83–0.96) [6,7]. The ARISTOTLE trial demonstrated apixaban’s superiority in both safety and mortality outcomes (HR 0.69; 95% CI 0.60–0.80) [1]. In local data, 62% of patients received NOACs, predominantly apixaban and rivaroxaban, while Warfarin was primarily prescribed to those with mechanical valves or cost-related limitations. Survey results showed 77% of NOAC users reported good adherence and 83% satisfaction, versus 52% adherence and 56% satisfaction among Warfarin users. INR-related follow-up visits accounted for 18% of Warfarin-associated hospital interactions.
Conclusion: NOACs offer a favourable safety and adherence profile compared to Warfarin, without compromising efficacy. While Warfarin remains relevant in select clinical scenarios, broader access to NOACs and improved patient education could optimize anticoagulation outcomes in diverse settings.
Keywords: Warfarin, NOACs, atrial fibrillation, stroke prevention, bleeding risk, patient adherence, INR monitoring